Cassava sciences announces positive top-line clinical results in phase 2 study evaluating simufilam in alzheimer's disease

Austin, texas, jan. 24, 2023 (globe newswire) -- cassava sciences, inc. (nasdaq: sava), a biotechnology company, today announced positive top-line phase 2 results for simufilam, its oral drug candidate for alzheimer's disease dementia. this was an open-label safety study with exploratory efficacy endpoints. the study enrolled over 200 patients with mild-to-moderate alzheimer's disease (mmse 16-26). study participants were administered open-label simufilam tablets 100mg twice daily for 1 year or more. endpoints were measured at baseline (study entry) and month 12.
SAVA Ratings Summary
SAVA Quant Ranking